

**NZX/ASX Announcement**

2 November 2022

**TruScreen Hosts Global Medical Symposium,  
Expands Reach in Vietnam**

Truscreen Group Limited (**NZX/ASX:TRU**) (TruScreen or Company) is pleased to announce successful completion of the first global virtual medical symposium to key opinion leaders from 7 countries, on cervical cancer screening.

The medical symposium was chaired by Professor Neville Hacker, one of the world leaders in gynaecology-oncology and a Founder of first multidisciplinary Australian Gynaecological Cancer Centre in Sydney in 1986. The speakers at the medical symposium included Associate Professor Michael Campion, Head of the Pre-Invasive Clinic at the Gynaecological Cancer Centre of the Royal Hospital for Women in Sydney, Professor Hextan Ngan from University of Hong Kong, Associate Professor Fei Chen of Peking Union Medical College Hospital in China, Dr Bernard Madzima, the CEO of the National AIDS Council in Zimbabwe and Dr Majed Alhudhud, the Director of Gynaecology Oncology Services at the Aryan Hospital Medical Group, Riyadh, Saudi Arabia.

The medical symposium, titled “Place of advanced technologies in screening for cervical cancer” had 132 registrations from Key Opinion Leaders from China, Mexico, Russia, Poland, Vietnam, Zimbabwe and Saudi Arabia. The medical symposium enabled professional discussions on TruScreen and its current clinical data and presented the success in cervical cancer screening programs in several countries.

The largest clinical study was reported by Associate Professor Fei Chen on the results of over 15,000 women and compared performance of TruScreen® Ultra to liquid-based cytology (LBC) and high risk HPV testing (hrHPV) in cervical cancer screening in China. The study found that for detection of CIN2+, TruScreen’s sensitivity was higher than that of LBC, 87.5% vs 66.5% ( $P < 0.001$ ) and specificity was higher than that of LBC and hrHPV testing, 88.4% vs 86.3% and 78.3% ( $P < 0.001$ ). In hrHPV positive women, regardless of genotype, TruScreen-positive women had a higher risk of detecting CIN2+ than the LBC positive women did while TruScreen negative women had a lower risk of detecting CIN2+ than the LBC normal women did. (*See NZX announcement of 5 April 2022 for full results*).

TruScreen has received approvals from the Ministry of Health (MOH) for 2 additional large hospitals in southern Vietnam: Tu Du Hospital in Ho Chi Minh City (HCMC) and Hau Giang Hospital in Hau Giang Province. These two influential hospitals will use TruScreen® Ultra for cervical cancer screening. The hospitals commenced using TruScreen® Ultra in their cervical cancer screenings as from October 2022.

Four TruScreen devices will be installed in the hospitals shortly. This will further accelerate MOH approvals for other public hospitals, including a further 4 hospitals which are currently in the evaluation process. Our distributor in Vietnam, is organizing two training seminars for medical clinicians, in HCMC and in Hanoi, during December 2022 in readiness for rolling out of TruScreen cervical cancer screening technology.



Dr Beata Edling, TruScreen CEO said, *“we are delighted with the success of our first global medical symposium on cervical cancer screening. This will be an annual event to allow our distributors to leverage the experience and success of fellow distributors and to share those successes with our global Key Opinion Leaders.”*

*“Vietnam will be a significant market for TruScreen, and we are now seeing good acceptance of our technology, post COVID. We will work closely with our distributor, on supporting our Key Opinion Leaders with all clinical data to optimise TruScreen® Ultra uptake in Vietnam. ”*

For more information, visit [www.truscreen.com](http://www.truscreen.com) or contact:

Dr Beata Edling  
Chief Executive Officer  
[beataedling@truscreen.com](mailto:beataedling@truscreen.com)

Guy Robertson  
Chief Financial Officer  
[guyrobertson@truscreen.com](mailto:guyrobertson@truscreen.com)

Julia Maguire  
Investor Relations  
[julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)

## About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a New Zealand-based medical device company that has developed an AI-enabled device that can detect precancerous and cancerous cervical changes in real-time via optical and electrical measurements of cervical tissue. Unlike many cervical screening technologies that have only triage/adjunct functionality, the TruScreen device is registered as a primary screening tool.

TruScreen's cervical screening technology effectively resolves many of the ongoing issues with conventional cytology, including failed samples, poor patient follow-up, patient discomfort, and the need for supporting laboratory infrastructure.

The device is CE-marked, meaning it meets EU safety, health and environmental protection standards required for sale and use throughout Europe. It is also National Medical Products Administration approved for sale in China. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen is currently targeting product sales to a range of low and middle-income countries, including China, Mexico, Vietnam, Russia, Zimbabwe and Saudi Arabia, where no large-scale cervical cancer screening programmes and infrastructure are currently in place. By doing so, the Company hopes to help improve the health and wellbeing of women worldwide.

To learn more, please visit: [www.truscreen.com/](http://www.truscreen.com/)